Results 31 to 40 of about 5,406 (200)

Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To observe the curative effect of aprepitant on chemotherapy-induced nausea and vomiting(CINV) and hemoglobin level in gynecological malignancy patients.
HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi   +7 more
doaj   +1 more source

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies

Cancer Biology & Medicine, 2021
Objective: Chemotherapy-induced nausea and vomiting (CINV) are common with doxorubicin-cyclophosphamide (AC) chemotherapy. Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine type-3 receptor ...
Winnie Yeo, Leung Li, Thomas KH Lau, Kwai T Lai, Vicky TC Chan, Kwan H Wong, Christopher CH Yip, Elizabeth Pang, Maggie Cheung, Vivian Chan, Carol CH Kwok, Joyce JS Suen, Frankie KF Mo   +12 more
doaj   +1 more source

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Cancer Medicine, 2023
Introduction Non‐inferiority of NEPA (fixed combination of NK1 receptor antagonist (RA), netupitant, and 5‐HT3RA, palonosetron) versus an aprepitant regimen was previously shown in a pragmatic study in patients receiving anthracycline cyclophosphamide ...
Laurent Zelek, Rudolph Navari, Matti Aapro, Florian Scotté   +3 more
doaj   +1 more source

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?

, 2020
Neurokinin-1 receptor (NK-1R) antagonists exert antitumor action, are safe and do not cause serious side-effects. These antagonists (via the NK-1R) exert multiple actions against cancer: antiproliferative and anti-Warburg effects and apoptotic, anti ...
Rafael Coveñas, Miguel Muñoz, Coveñas, Rafael, Muñoz, Miguel   +3 more
core   +1 more source

Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability

, 2009
Background. the neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents ...
Valentine, Jack, Evans, Judith K., Chua, Vickey, Adolescent Aprepitant Canc Study G, Gore, Lia, Carides, Alexandra D., Oxenius, Bettina, Hemenway, Molly, Taylor, Arlene, Schissel, Debra, Petrilli, Antonio [UNIFESP], DeVandry, Suzanne, Chawla, Sant   +12 more
core   +1 more source

Retrospective safety evaluation of aprepitant in pediatric patients receiving vincristine or doxorubicin: a feasibility study [PDF]

, 2022
Pharmacy residents have the opportunity to complete a research project during their residency training, which provides them with skills on how to conduct and manage a research project.
Koo, Alicia, Volpe, Jocelyne, Dupuis, L Lee, Patel, Priya, Lamb, Julia, Brzezinski, Jack   +5 more
core   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary Syndrome [PDF]

, 2012
Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in ...
Fernandes, I., Torres, T., Lima, M., Selores, M., Alves, R.   +4 more
core   +1 more source

Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron

Drug Design, Development and Therapy, 2021
Thomas Ottoboni, 1 Laura Lerner, 1 Arlene Santhouse 2 1Pharmaceutical and Translational Science, Heron Therapeutics, Inc, San Diego, CA, USA; 2Medical Affairs, Heron Therapeutics, Inc, San Diego, CA, USACorrespondence: Thomas OttoboniPharmaceutical and
Ottoboni T, Lerner L, Santhouse A
doaj  

Investigation of the mechanisms and modulation of irinotecan‐induced emesis in Suncus murinus

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Irinotecan is a widely used chemotherapeutic agent that frequently causes nausea and emesis. Its emetic mechanism of action is poorly understood and the choice of drugs to reduce nausea and emesis is largely empirical. Experimental Approach Using Suncus murinus, we examined (i) the dose–response and temporal profile of ...
Zengbing Lu, Julia Y. H. Liu, Yasuhiro Nakagami, Zitong Li, Xiaofei Huang, Man P. Ngan, Dexuan Cui, John A. Rudd   +7 more
wiley   +1 more source